ReviewDisease markers2018
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
Review in Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.Cancer metastasis reviews · 2026Pooled it
- The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms.The American journal of surgical pathology · 2025Guideline
- Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.Frontiers in public health · 2022Trial
- Urinary bladder invasion secondary to dissemination of gallbladder cancer: an unusual presentation.Clinical journal of gastroenterology · 2026Article
- Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report.Current oncology (Toronto, Ont.) · 2026Article
- Urachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases.Current oncology (Toronto, Ont.) · 2026Article
- Histotype-specific incidence and survival of urothelial carcinoma-an analysis of the German North Rhine-Westphalia Cancer Registry.ESMO real world data and digital oncology · 2026Article
- Finding of a Urachal Cyst in a Patient Presenting With an Acute Abdomen due to Appendicitis.Case reports in surgery · 2026Article
- Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review.Frontiers in oncology · 2026Article
- Grading of bladder cancer: updates, controversies and practical solutions.Histopathology · 2026Review
- Robot‑assisted laparoscopic partial cystectomy for urachal carcinoma: A case report.Oncology letters · 2025Article
- Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma.NPJ precision oncology · 2025Article
- Article
- [Rare tumors and tumor types of the urinary system in the 5th edition of the WHO classification 2022].Pathologie (Heidelberg, Germany) · 2024Article
- Urachal mixed adenocarcinoma and small cell neuroendocrine carcinoma with widespread metastasis and resistance to chemotherapy: a case report.Diagnostic pathology · 2024Article
- Acute Glomerulonephritis as a Paraneoplastic Syndrome Secondary to Urachal Adenocarcinoma: An Unknown Entity.Cureus · 2024Article
- Rare case of enteric type of urachal adenocarcinoma: A case report.Urology case reports · 2024Article
- Urachal adenocarcinoma with cervical invasion misdiagnosed as primary cervical adenocarcinoma: a case report and literature review.Frontiers in oncology · 2024Article
- Modern methods in managing urachal adenocarcinoma.Current urology · 2023Article
- Urachal Adenocarcinoma: a Case Report and Review of the Literature.Indian journal of surgical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
Abstract
Urachal cancer (UrC) is a rare but aggressive cancer. Due to overlapping histomorphology, discrimination of urachal from primary bladder adenocarcinomas (PBAC) and adenocarcinomas secondarily involving the bladder (particularly colorectal adenocarcinomas, CRC) can be challenging. Therefore, we aimed to give an overview of helpful (immunohistochemical) biomarkers and clinicopathological factors in addition to survival analyses and included institutional data from 12 urachal adenocarcinomas. A PubMed search yielded 319 suitable studies since 1930 in the English literature with 1984 cases of UrC including 1834 adenocarcinomas (92%) and 150 nonadenocarcinomas (8%). UrC was more common in men (63%), showed a median age at diagnosis of 50.8 years and a median tumor size of 6.0 cm. No associations were noted for overall survival and progression-free survival (PFS) and clinicopathological factors beside a favorable PFS in male patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.